{"id":"W4391430347","doi":"10.1016/j.ejca.2024.113585","title":"Prognostic and predictive value of non-steroidal anti-inflammatory drugs in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma","year":2024,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Manchester Biomedical Research Centre; Array BioPharma; Ipsen; Genentech; Deutsche Krebshilfe; Eisai; National Institute for Health and Care Research; Italfarmaco; Seagen; Sanofi Pasteur; Galecto; SkylineDx; Cancer Research UK; NeraCare; Sun Pharma; Regeneron Pharmaceuticals; Sanofi; Pfizer; InflaRx; Les Laboratories Pierre Fabre; Daiichi Sankyo Europe; Bayer; Bristol-Myers Squibb; AstraZeneca; Amgen","keywords":"Medicine; Pembrolizumab; Placebo; Internal medicine; Hazard ratio; Adverse effect; Incidence (geometry); Melanoma; Gastroenterology; Clinical trial; Surgery; Oncology; Cancer; Immunotherapy; Confidence interval; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002453722,0.0002008763,0.0005867361,0.0003981805,0.00003401354,0.0000302416,0.0002248728,0.00005125393,0.00006961651],"category_scores_gemma":[0.0001531566,0.0001354865,0.0001617515,0.0004156394,0.0002318402,0.0001609397,0.00004284077,0.0006198034,7.06454e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001631128,"about_ca_system_score_gemma":0.0005222348,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002030739,"about_ca_topic_score_gemma":0.00006204055,"domain_scores_codex":[0.9971406,0.000748491,0.001077419,0.0002109325,0.0005856547,0.0002368381],"domain_scores_gemma":[0.9985391,0.0004181034,0.0005951084,0.0002237197,0.0001454766,0.00007846834],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.924125,0.0004525838,0.005666417,0.0003961315,0.001047569,0.001281998,0.01520772,0.0002053994,0.01849623,0.00002074903,0.0007915982,0.03230862],"study_design_scores_gemma":[0.7169983,0.01731234,0.2437263,0.004065045,0.0008741931,0.0001043677,0.003330947,0.001569595,0.008372558,0.0000104991,0.00333163,0.0003041759],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9912768,0.005636235,0.00005645239,0.0003273661,0.0009814437,0.0008429869,0.00008045378,0.00000876112,0.0007895204],"genre_scores_gemma":[0.9969836,0.002231302,0.00003168263,0.00003543699,0.0005657822,0.000009655295,0.000004716402,0.00003818742,0.00009957387],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2380599,"threshold_uncertainty_score":0.5524978,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01244482816295829,"score_gpt":0.2935422822969203,"score_spread":0.281097454133962,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}